Abstract

In the present study, the synthesis of benzimdazolyl 2-amino-1,3,4-oxadiazole derivatives (5a-j) and their in vitro anticancer activities against HeLa, MCF7, A549, and HEK293 cell lines were reported. Compound 5f showed most promising anticancer activity with IC₅₀ values 4.68 ± 0.04, 4.16 ± 0.02, 5.40 ± 0.08 µM against the HeLa, MCF-7, and A549 cell lines respectively. Compounds 5b and 5e have also shown excellent anticancer activity with IC₅₀ values 6.07 ± 0.028, 5.30 ± 0.09, 7.16 ± 0.061 µM and 7.56 ± 0.073, 7.20 ± 0.048, 11.30 ± 0.018 µM against the HeLa, MCF-7, and A549 cell lines respectively. The rest of the compounds displayed moderate to good anticancer activity. The tested compounds were nontoxic to normal HEK293 cell lines, and even the more active compounds (5b, 5e, and 5f) also less toxic on HEK-293 cells. Molecular docking results of the synthesized compounds with the target EGFR protein were also discussed.

摘要

在本研究中，报道了苯并咪唑基 2-氨基-1,3,4-恶二唑衍生物(5a-j)的合成及其对 HeLa、MCF7、A549 和 HEK293 细胞系的体外抗癌活性。化合物5f显示出最有希望的抗癌活性，对 HeLa、MCF-7 和 A549 细胞系的 IC ₅₀值分别为 4.68 ± 0.04、4.16 ± 0.02、5.40 ± 0.08 µM。化合物5b和5e也显示出优异的 IC _{50抗癌活性}对 HeLa、MCF-7 和 A549 细胞系的值分别为 6.07 ± 0.028、5.30 ± 0.09、7.16 ± 0.061 µM 和 7.56 ± 0.073、7.20 ± 0.048、11.30 ± 0.018 µM。其余化合物显示出中等至良好的抗癌活性。测试的化合物对正常的 HEK293 细胞系无毒，甚至活性更高的化合物（5b、5e和5f）对 HEK-293 细胞的毒性也较小。还讨论了合成化合物与靶EGFR蛋白的分子对接结果。